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countries who had experienced a self-reported non-severe hypoglycaemic event in 
the past 4 weeks were eligible to participate in a nocturnal (N) and/or daytime (D) 
hypoglycaemia survey. In Algeria the surveys were conducted face-to-face and 68 
people responded (56 respondents for the nocturnal survey; 57 respondents for the 
daytime survey). Results: In the Algerian cohort 73%/74% (N/D) of respondents 
had type 2 diabetes, mean age was 41 years/42 years (N/D), mean weight was 68.6 
kg/69.4 kg (N/D) and 29%/33% (N/D) were male. Participants received treatment with 
insulin (24%/31% [N/D]), oral medication (76%/69% [N/D]) and/or diet and exercise 
(10%/5% [N/D]), and 80%/81% (N/D) had no diabetes-related medical complications. 
The majority of respondents experienced a hypoglycaemic event at least once a 
month 80%/95% (N/D). Among those fasting during the month of Ramadan (n= 37/39), 
24%/31% (N/D) experienced hypoglycaemia more often compared to a usual month. 
After a non-severe nocturnal (N)/daytime (D) hypoglycaemic event, 8%/18% (N/D) 
decreased their insulin dose, 27%/19% (N/D) contacted a health care professional, 
and respondents reported using, on average, 6/4 (N/D) extra blood glucose tests 
the following week. Although 54%/39% (N/D) reported a high level of fear of expe-
riencing a hypoglycaemic event, fewer reported that a daytime event had a high 
impact on their daily routine compared with a nocturnal event (38%/21% [N/D]). 
Among the 27%/26% (N/D) respondents who worked for pay, 27%/46% (N/D) went 
to work late or left early and 47%/13% (N/D) missed ≥ 1 full days due to a non-severe 
event. ConClusions: In Algeria, nocturnal and daytime non-severe hypoglycaemic 
events severely impact health care utilisation, work productivity, and quality of life 
in people with diabetes.
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objeCtives: Two surveys were conducted to understand the effects of non-severe 
hypoglycaemia on utilisation of health care services and quality of life in people 
with diabetes in Bangladesh. Methods: People with diabetes from five different 
countries who had experienced a non-severe hypoglycaemic event in the past 4 
weeks were asked to take part in a nocturnal (N) and/or daytime (D) hypoglycaemia 
survey. In the Bangladeshi subgroup, 92 people responded (51 respondents for the 
nocturnal survey, 50 for the daytime survey). Surveys were conducted face-to-face. 
All information, including hypoglycaemic events, was self-reported. Results: In 
the Bangladeshi cohort, 80%/90% (N/D) had type 2 diabetes, 63%/50% (N/D) were 
male, mean age was 46 years/49 years (N/D), mean weight was 62.1 kg/62.2 kg (N/D), 
100%/98% (N/D) were insulin users and more than half of respondents had eye 
problems as a result of diabetes (63%/54% [N/D]). Non-severe hypoglycaemic epi-
sodes were experienced at least once weekly by 24%/40% (N/D) and at least once 
a month by 58%/80% (N/D) of respondents. After a non-severe nocturnal/daytime 
hypoglycaemic event, 16%/22% (N/D) decreased their insulin dose and 41%/32% 
(N/D) contacted a health care professional. Almost a third of respondents reported 
a high level of fear of future hypoglycaemic events (35%/16% [N/D]), and almost a 
quarter (22%/20% [N/D]) reported that hypoglycaemic events had a high impact on 
their daily routine. Of respondents who worked for pay (n= 17/17), 94%/76% (N/D) 
reported a high/medium impact on work productivity following a hypoglycaemic 
episode. Median time to return to sleep following a nocturnal event was 60 minutes; 
24% reported the event had a high impact on sleep, and 71% had difficulty focus-
ing at work the next day. ConClusions: In Bangladesh, nocturnal and daytime 
non-severe hypoglycaemic events impact quality of life, utilisation of health care 
resources and productivity in people with diabetes.
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objeCtives: Empagliflozin, an oral antidiabetic drug, inhibits the sodium-glucose 
cotransporter 2 and promotes urinary glucose excretion. Six of the phase 3 stud-
ies assessed efficacy and safety, including health outcomes, of empagliflozin as 
monotherapy or in combination with other oral antidiabetic treatments. The objec-
tive was to evaluate the effect of treatment on patient utility and health profiles 
(measured by the EQ-5D) and health care resource utilization (HCRU). Methods: 
Descriptive analyses were performed for each individual trial and pooled across tri-
als. Multivariable analyses were performed using linear mixed models for repeated 
measurements to account for the longitudinal data and significant baseline char-
acteristics. Results: The overall completion rate of the EQ-5D utility index and 
EQ-5D VAS at 24 weeks was above 90% in all treatment groups across trials. Patients’ 
utility and health profiles were high at baseline; most patients reported no problems 
with self-care [97% of empagliflozin; 96% of placebo]; the most commonly reported 
problem was pain/discomfort [35% of empagliflozin, 36% of placebo reported at least 
some problems]. After 24 weeks, adjusted for baseline covariates, there were few 
statistically significant differences between empagliflozin and placebo in patient 
utility (0.026, p= 0.0268) and health profiles (3.4, p= 0.0062) across trials. These dif-
ferences were positive in three out of six trials in patient utility and in all trials in 
health profiles. For HCRU, the largest percentages of hospitalizations or outpa-
tient visits were observed for general physician visits (~15%) and specialist visits 
(~10%) across treatment groups. Most of the resources used were not diabetes-
related. ConClusions: Differences in patient utility and health profiles between 
empagliflozin and placebo over 24 weeks were in general positive but small, which 
was not unexpected given that the majority of patients reported no problems at 
baseline. The percentage of patients with hospitalizations or outpatient visits was 
low with similar use reported among empagliflozin and placebo treatment groups.
regression analysis was used to control for demographic and clinical covari-
ates. Results: The final sample (unweighted N= 7003; weighted N= 14.6 million) 
had a mean age (±SE) = 61.2 (±0.2) years, mean BMI (±SE)= 32.2 (±0.1), and 50.4% 
were males. There was a significant difference in both the PCS-12 and MCS-12 
scores of patients by BMI, controlling for covariates. Being obese (PCS = 40.1) 
or morbidly obese (PCS = 35.6) were significantly associated with lower PCS-12 
scores compared to normal weight patients (PCS = 41.0, p < 0.001 for both), while 
being overweight was significantly associated with higher MCS-12 scores com-
pared to being of normal weight (MCS = 50.9 vs 48.9, p = 0.038). ConClusions: 
Among diabetes patients, overweight patients had significantly higher mental 
health scores compared to their peers with normal weight, while being at least 
obese was significantly associated with lower physical health scores compared 
to non-obese patients.
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objeCtives: Dapagliflozin, a novel, selective, oral sodium-glucose co-transporter 2 
(SGLT2) inhibitor, lowers glycated hemoglobin (HbA1c) along with reduction in body 
weight. This study evaluated health-related quality of life (HRQOL) among type 2 
diabetes mellitus (T2DM) patients treated with dapagliflozin in triple therapy during 
a 24-week period. Methods: Patients with T2DM (mean age 61 years, 49% men, 
96% with body mass index ≥ 25 kg/m2) who had inadequate glycemic control on 
combination of metformin (MET) and sulfonylurea (SU) were enrolled in a 24-week, 
international, double-blind, randomized, placebo-controlled study (NCT01392677) 
to evaluate the effect of dapagliflozin in combination with MET plus SU on HbA1c 
and body weight. Patients completed the EuroQol Group EQ-5D survey at baseline 
and at week 24 for evaluation as a secondary objective. Patients treated with dapa-
gliflozin 10 mg + MET + SU (n = 108) were compared with patients treated with 
placebo + MET + SU (n = 108), based on ANCOVA model with treatment group as an 
effect and baseline value as a covariate. Results: EQ-5D visual analog scale (VAS, 
0-100) baseline means (SD) were 74.6 (20.0) and 73.1 (20.5) for the dapagliflozin and 
placebo groups, respectively. Corresponding 24-week values were 78.4 (15.2) and 
76.8 (16.9), respectively. VAS scores improved in both groups from baseline to week 
24; however, there was no significant difference between groups (0.9; CI: -2.9, 4.8; 
p-value: 0.63) in adjusted change from baseline. EQ-5D index (scores 0-1) baseline 
means were 0.84 (0.16) and 0.85 (0.16) for dapagliflozin and placebo, respectively. 
Corresponding 24-week values were 0.83 (0.17) and 0.83 (0.16), respectively. There 
was no difference in adjusted change from baseline between treatment groups (0.01; 
CI: -0.03, 0.05; p-value: 0.68). ConClusions: Similar to other dapagliflozin studies, 
patients in the present study maintained high HRQOL scores with dapagliflozin 
over a 24-week period.
PDB111
The associaTion of healTh-relaTeD qualiTy of life (hrqol) anD 
achievemenT of Disease managemenT goals in The TreaTmenT of TyPe 
2 DiaBeTes melliTus (T2Dm)
Traina S.B.1, Neslusan C.1, Slee A.2
1Janssen Global Services, LLC, Raritan, NJ, USA, 2Axio, Seattle, WA, USA
objeCtives: Guidelines for T2DM specify goals for biomarkers (e.g., A1c, SBP, LDL, 
weight), emphasize the avoidance of hypoglycemia, and acknowledge the critical 
role that individuals play in managing their disease. This study explored whether 
goal attainment was associated with HRQoL, using data from a previously reported 
52 week study of canagliflozin 100 mg and 300 mg versus glimepiride with met-
formin and background diet and exercise. Methods: This post-hoc analysis 
included subjects for whom baseline and post-baseline clinical and HRQoL data 
were available (n= 1111/1450). HRQoL was measured using the Impact of Weight 
on Quality of Life – Lite (IWQOL-Lite) and Short Form 36 (SF-36) questionnaires. 
Distributions of subjects achieving/not achieving the following individual goals: 
A1c < 7%, SBP < 130 mmHg, LDL-C < 100 mg/dL, no symptomatic hypoglycemia, 
and any weight loss were calculated for pooled canagliflozin arms and glimepiride. 
The least-square mean (LSM) change in IWQOL-Lite Total and SF-36 physical (PCS) 
and mental (MCS) composite scores were calculated by goal status, adjusting for 
baseline score, trial stratification factors, and treatment. Results: The proportions 
of subjects meeting biomarker goals did not differ by treatment at baseline. At 52 
weeks, the proportion meeting A1c, SBP, LDL, no symptomatic hypoglycemia, and 
weight goals were 61.5, 64.7, 40.3, 97.7, and 87.2, respectively for canagliflozin and 
58.2, 53.3, 48.9, 73.0, and 28.1, respectively for glimepiride. LSM change in IWQOL-Lite 
by goal status was statistically different for weight loss (Δ = 2.1; 95% CI: 0.5, 3.7). 
LSM change in PCS did not differ by goal status. LSM change in MCS was statistically 
significant for symptomatic hypoglycemia (Δ = 2.7; 95% CI: 1.0, 4.3). ConClusions: 
These results show that the choice of glucose lowering agent can impact goal attain-
ment and suggest that therapies offering weight loss and avoidance of symptomatic 
hypoglycemia can have a positive impact on HRQoL.
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objeCtives: To examine the effects of nocturnal and daytime non-severe hypo-
glycaemic events on utilisation of health care services and patient quality of life in 
people with diabetes in Algeria. Methods: People with diabetes from five different 
